Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 21%
Buy 32%
Hold 47%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care is in a strong position for growth and profitability, thanks to success in the pharmacy channel and the potential of their new Mobi Tubeless pump. The company's focus on the diabetes market and potential for margin expansion through their DME channel make them a solid investment opportunity for the future. However, TNDM may face challenges from competition and converting patients to the pharmacy channel for revenue growth to continue.

Bears say

Tandem Diabetes Care is facing multiple risks, including intense competition in a rapidly changing market and the potential threat of GLP-1s to insulin delivery devices. The company's dependence on a concentrated product line and the need to retain its customer base for sustainable growth are also risks. In addition, Tandem's reliance on third-party suppliers exposes it to potential supply chain disruptions, and a lack of reimbursement from payers could negatively impact its business. In light of these risks, it may be challenging for Tandem to achieve consistent profitability.

TNDM has been analyzed by 19 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 32% recommend Buy, 47% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 19 analysts, TNDM has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.